The blockade of the PI3K/AKT/mTOR signaling pathway, which is upregulated in different types of tumors, including the GC-resistant ALL (see section Metabolic Re-programming and Upregulation of the PI3K/Akt/mTOR Pathway Is Related to GC Resistance in ALL), is proposed as a rational therapeutic approach (153, 273). This evidence concerns the gene PIK3CD and acute lymphoblastic leukemia.